NCT02708004已完成1 期
A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Body weight
研究概览
简要总结
This clinical study will be conducted to evaluate the effect of ACT-132577 on fluid homeostasis in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent
- •Healthy on the basis of medical history, physical examination, cardiovascular assessments and hematology, clinical chemistry, and urinalysis tests
- •Body mass index between 20.0 and 25.0 kg/m2 (inclusive) at screening
排除标准
- •Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
研究组 & 干预措施
ACT-132577
Experimental
3 different dose levels
干预措施: Aprocitentan (Drug)
Placebo
Placebo Comparator
Matching active drug
干预措施: Placebo (Other)
结局指标
主要结局
Body weight
时间窗: from Day 1 to Day 9
Change from baseline
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" EpisodesIdiopathic Parkinson's DiseaseNCT01617135Acorda Therapeutics25
已完成
1 期
Study of AT-752 in Healthy SubjectsDengueNCT04722627Atea Pharmaceuticals, Inc.65
已完成
1 期
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesType 1 DiabetesNCT05794581Carmot Therapeutics, Inc.32
已完成
2 期
A Study of CDX-0159 in Patients With Chronic Inducible UrticariaChronic Inducible UrticariaNCT05405660Celldex Therapeutics196
终止
2 期
Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic ConstipationChronic ConstipationNCT00501241Procter and Gamble214
